Back

Myeloid-derived β-hexosaminidase is essential for neuronal health and lysosome function: implications for Sandhoff disease

Tsourmas, K. I.; Butler, C. A.; Kwang, N. E.; Sloane, Z. R.; Dykman, K. J. G.; Maloof, G. O.; Prekopa, C. A.; Krattli, R. P.; El-Khatib, S. M.; Swarup, V.; Acharya, M. M.; Hohsfield, L. A.; Green, K. N.

2024-10-22 neuroscience
10.1101/2024.10.21.619538 bioRxiv
Show abstract

Lysosomal storage disorders (LSDs) are a large disease class involving lysosomal dysfunction, often resulting in neurodegeneration. Sandhoff disease (SD) is an LSD caused by a deficiency in the {beta} subunit of the {beta}-hexosaminidase enzyme (Hexb). Although Hexb expression in the brain is specific to microglia, SD primarily affects neurons. To understand how a microglial gene is involved in maintaining neuronal homeostasis, we demonstrated that {beta}-hexosaminidase is secreted by microglia and integrated into the neuronal lysosomal compartment. To assess therapeutic relevance, we treated SD mice with bone marrow transplant and colony stimulating factor 1 receptor inhibition, which broadly replaced Hexb-/- microglia with Hexb-sufficient cells. This intervention reversed apoptotic gene signatures, improved behavior, restored enzymatic activity and Hexb expression, ameliorated substrate accumulation, and normalized neuronal lysosomal phenotypes. These results underscore the critical role of myeloid-derived {beta}- hexosaminidase in neuronal lysosomal function and establish microglial replacement as a potential LSD therapy.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.